Gilead Sciences Inc.
South Africa has made history by becoming the first African country to register the revolutionary twice-a-year anti-HIV jab, lenacapavir (LEN). This groundbreaking medicine offers almost full-proof protection against HIV transmission through sex for HIV-negative individuals and is also safe for pregnant and breastfeeding women to use. The registration of LEN
Biological products industry
Gilead Sciences Inc. has been developing lenacapavir, a first-in-class HIV capsid inhibitor, for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). The research concluded that lenacapavir holds potential for helping to end new HIV infections around the world. The company is committed to working with scientists, clinicians, communities, advocates,
Dr. Reddy's Laboratories Ltd.
A groundbreaking partnership between Dr. Reddy's Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI will make the HIV prevention tool, injectable lenacapavir, available at a cost of US$40 per year in 120 low- and middle-income countries starting in 2027. The injection has shown exceptional
Health care industry
Louisiana Attorney General Liz Murrill has joined a coalition of 48 other attorneys general in securing a $202 million settlement from Gilead Sciences, Inc. for an illegal kickback scheme to promote its HIV medications. The scheme involved Gilead providing incentives to healthcare providers to prescribe its medications, resulting in millions
Health care industry
Attorney General Kwame Raoul led a bipartisan coalition of 49 attorneys general in securing a $202 million multistate settlement with Gilead Sciences Inc. for an illegal kickback scheme to promote its HIV medications. The settlement provides $49 million for Medicaid programs nationwide, including over $925,000 for Illinois. The investigation
Health care industry
The state of New Jersey, along with a coalition of 48 other attorneys general, has secured a $202 million settlement from Gilead Sciences, Inc. (Gilead), for running an illegal kickback scheme to promote its HIV medications. The settlement, reached in coordination with the U.S. Department of Justice and approved
Health care industry
Connecticut Attorney General William Tong, leading a coalition of 48 other attorneys general, has secured a $202 million settlement with Gilead Sciences, Inc. over an illegal kickback scheme involving its HIV medications. The settlement was reached in coordination with the U.S. Department of Justice and provides $49 million for
Gilead Sciences Inc.
Washington-based non-profit medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is sounding the alarm over the limited access to the HIV prevention medicine lenacapavir, partly due to restrictive patent licensing agreements imposed by the developer, Gilead Sciences. The organization welcomes the World Health Organization's (WHO) recommendation
Biological products industry
Gilead Sciences Inc has showcased the efficacy and tolerability of twice-yearly injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP) across diverse populations, including pregnant and lactating women, adolescents, and young adults. The new data from the Phase 3 PURPOSE trials highlighted zero HIV infections among pregnant and breastfeeding participants on
Drug approval
The US Food and Drug Administration has approved lenacapavir, an injectable drug that offers long-lasting protection against HIV infection. This new treatment marks a significant advancement in expanding prevention options for people at risk of HIV infection, offering a convenient and highly effective alternative to daily pills. Key Takeaways: * Lenacapavir
Biological products industry
The Food and Drug Administration has approved a new, twice-a-year injectable HIV prevention medication, lenacapavir, which has been shown to be highly effective in preventing new infections. The medication, which will be marketed as Yeztugo, offers a more convenient alternative to existing daily HIV prevention pills, which have adherence rates
Biological products industry
Lenacapavir, a first-in-class HIV capsid inhibitor, is currently under development by Gilead Sciences for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). According to Gilead Sciences, clinical trial results demonstrate the potential of lenacapavir in ending new HIV infections worldwide. The company is committed to working with various stakeholders
